Natera, Inc.
$206.53
▲
0.54%
2026-04-22 10:12:13
www.natera.com
NMS: NTRA
Explore Natera, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$29.47 B
Current Price
$206.53
52W High / Low
$256.36 / $131.81
Stock P/E
—
Book Value
$12.26
Dividend Yield
—
ROCE
-15.84%
ROE
-14.32%
Face Value
—
EPS
$-1.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,135
Beta
1.68
Debt / Equity
12.52
Current Ratio
3.39
Quick Ratio
3.24
Forward P/E
-272.56
Price / Sales
11.86
Enterprise Value
$26.5 B
EV / EBITDA
-97.62
EV / Revenue
11.49
Rating
Strong Buy
Target Price
$258.58
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Labcorp Holdings Inc. | $271.17 | 25.93 | $22.36 B | 1.07% | 9.74% | 10.51% | $293.72 / $209.38 | $104.86 |
| 2. | Advanced Biomed Inc. | $5 | 1.49 | $6.55 M | — | — | 80.18% | $48.8 / $3.61 | $8.76 |
| 3. | bioAffinity Technologies, Inc. | $2.69 | — | $12.87 M | — | -131.93% | -3.02% | $17.44 / $0.69 | $1.62 |
| 4. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 5. | NeoGenomics, Inc. | $8.23 | — | $1.06 B | — | -6.93% | -12.43% | $13.74 / $4.72 | $6.49 |
| 6. | iSpecimen Inc. | $0.13 | — | $4.05 M | — | -355.55% | -3.28% | $3.18 / $0.1 | $0.31 |
| 7. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 665.5 M | 592.18 M | 546.6 M | 501.83 M | 476.06 M | — |
| Operating Profit | -22.79 M | -97.58 M | -110.37 M | -79.18 M | -64.74 M | — |
| Net Profit | 47.26 M | -87.54 M | -100.94 M | -66.94 M | -53.77 M | — |
| EPS in Rs | 0.33 | -0.62 | -0.71 | -0.47 | -0.38 | -0.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.31 B | 1.7 B | 1.08 B | 820.22 M |
| Operating Profit | -309.91 M | -222.29 M | -446.25 M | -541.04 M |
| Net Profit | -208.16 M | -190.43 M | -434.8 M | -547.8 M |
| EPS in Rs | -1.47 | -1.34 | -3.07 | -3.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.4 B | 1.66 B | 1.44 B | 1.39 B |
| Total Liabilities | 685.93 M | 465.31 M | 676.37 M | 688.73 M |
| Equity | 1.71 B | 1.2 B | 765.33 M | 705.74 M |
| Current Assets | 1.5 B | 1.38 B | 1.26 B | 1.21 B |
| Current Liabilities | 441.23 M | 344.05 M | 307.27 M | 310.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 215.3 M | 135.66 M | -246.96 M | -431.5 M |
| Investing CF | -132.21 M | 137.62 M | 168.5 M | 330.34 M |
| Financing CF | 47.46 M | 30.2 M | 254.46 M | 482.64 M |
| Free CF | 76.11 M | 58.75 M | -286.15 M | -479.2 M |
| Capex | -139.19 M | -76.92 M | -39.2 M | -47.7 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 56.75% | 31.99% | — | — |
| Earnings Growth % | 56.2% | 20.63% | — | — |
| Profit Margin % | -11.22% | -40.16% | -66.79% | — |
| Operating Margin % | -13.1% | -41.22% | -65.96% | — |
| Gross Margin % | 60.3% | 45.52% | 44.37% | — |
| EBITDA Margin % | -8.73% | -36.75% | -63.5% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.